Pharvaris (PHVS) Research & Development (2025 - 2026)

Pharvaris posted quarterly Research & Development of -$35.3 million for Q1 2026, down 8.59% year-on-year from -$38.6 million in Q1 2025, and down 8.59% on a QoQ basis from -$32.5 million in Q1 2025.

Pharvaris (PHVS) has 2 years of Research & Development data on file, last reported at -$35.3 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 626,092.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 4.32 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -101.30 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 1.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 961.60 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -2.30 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.54 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 364.87 Mn
10 Pharvaris 267.74 Mn -73.74 Mn - -35.31 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -35.31 Mn
Mar 31, 2025 -32.52 Mn